To our knowledge, this is the first report of a breast cancer patient with a complete and sustained response to selective, RET-targeted therapy and adds to the diversity of RET fusion–positive tumor types that may benefit from selective RET inhibition. The gene discussed is RET; the disease is breast carcinoma.